
Cameron Gardner
SVP of R&D focused on cell and gene therapy
camerongardner
Boston, Massachusetts
Joined January 2026
Network
1.8K connectionsEWRAJE
KDASJM
NELRMC
JEMCKK
EWASMG
ACSBEK
KDXC
Summary
Cameron Gardner is a senior leader in research and development within the biotechnology sector, currently serving as Senior Vice President of R&D at JURA Bio, Inc. His expertise spans I/O, Cell and Gene Therapy, and Biologics Discovery, with a strategic focus on developing novel therapeutics for autoimmune diseases and T cell leukemias and lymphomas. He has progressed through various leadership roles at JURA Bio, demonstrating a strong trajectory in guiding scientific innovation. google+2
With a robust academic background, Cameron possesses a PhD in Clinical Medicine (Immunology) from the University of Oxford and specialized training in synthetic biology from Harvard Medical School. This foundational knowledge in immunology and synthetic biology underpins his work in gene and cell therapy development, enabling him to contribute significantly to cutting-edge biological research and its therapeutic applications. orcid+3
Cameron's research contributions include significant work in gene editing, particularly for severe combined immunodeficiency, and the development of artificial thymic organoid systems for T-cell differentiation studies. His publications reflect involvement in manufacturing-aware generative model architectures for biological sequence design, showcasing his engagement with advanced computational and biological engineering techniques. orcid+2
Work
Education
Writing
Manufacturing-aware generative model architectures enable biological sequence design and synthesis at Petascale
January 1, 2024Genetically corrected RAG2-SCID human hematopoietic stem cells restore V(D)J-recombinase and rescue lymphoid deficiency
January 1, 2024Gene editing rescues in vitro T cell development of RAG2-deficient induced pluripotent stem cells in an artificial thymic organoid system
January 1, 2021Artificial thymic organoids represent a reliable tool to study T-cell differentiation in patients with severe T-cell lymphopenia
January 1, 2020Design, synthesis, and testing toward a 57-codon genome
January 1, 2016A miniaturized microbial fuel cell with three-dimensional graphene macroporous scaffold anode demonstrating a record power density of over 10000 W mโ 3
January 1, 2016Similar profiles
MR
Michael Retchin
Founder at NewCo
19.3K connections
AEAaron Edwards
Scientific Advisory Board Member at RNAlead
6.9K connections
MAMilad Alucozai
Co-Founder & General Partner at Pamir Ventures
31K connections
ERElliot Roth
Founder at Biopunk House
25.3K connections
PMPatrick Malone
20.1K connections
DBDavid Berry
Managing Partner at Averin
23.7K connections